Hangzhou Tianmushan Pharmaceutical Enterprise Co LtdSSE: 600671

Report for Q1 2026

Apr 30, 2026 · Issued by Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd via Shanghai Stock Exchange

Filed with SSE · Apr 30, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-261

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd on 6ix

Earlier from Hangzhou Tianmushan Pharmaceutical Enterprise

Announcement on Purchasing Liability Insurance for Directors and Senior Management MembersApr 18
Announcement on Progress in Guarantees Provided for the Company's and Its Subsidiary's Application for Comprehensive Credit Line from Banks and Other Financial Institutions in 2025Mar 18
Announcement on Abnormal Fluctuations in Stock TradingJan 22
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025Dec 23, 2025
Announcement on Obtaining Notice of Approval for Re-Registration of Drug by Wholly-owned SubsidiaryDec 19, 2025

Later from Hangzhou Tianmushan Pharmaceutical Enterprise

Announcement on Resolutions of the 2025 Annual General MeetingMay 9
Announcement on Convening Performance Briefing for 2025 and Q1 2026May 14
Announcement on Listing and Circulation of Shares Subject to Lock-Up from Shareholding ReformMay 30
Announcement on Resolutions of the 20th Meeting of the 12th Board of DirectorsJun 12
Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual ReportJun 19

All Hangzhou Tianmushan Pharmaceutical Enterprise news releases

Follow Hangzhou Tianmushan Pharmaceutical Enterprise into a list and get an email when it puts out news.

Follow Hangzhou Tianmushan Pharmaceutical Enterprise